Global Breast Cancer Monoclonal Antibodies Market 2016-2020

  • Published: Sep 2016
  • Pages: 88
  • SKU: IRTNTR10205

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

This market research report identifies players like F. Hoffmann-La Roche, Amgen, and Mylan to be the key vendors in the global breast cancer mAbs market. This research report also presents a detailed segmentation of the market by type (naked and conjugated mAbs), by end-users (hospitals and retail pharmacies), and by geography (the Americas, APAC, and EMEA).

Overview of the global breast cancer monoclonal antibodies (mAbs) market

Market research analysts at Technavio have predicted that the global breast cancer monoclonal antibodies (mAbs) market will grow at a CAGR of around 8% between 2016 and 2020.  The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs), including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.

The breast cancer mAbs market in APAC will witness a high growth rate during the forecast period due to the better market penetration of breast cancer mAbs and biosimilars in emerging economies, especially in Japan, Australia, India, South Korea, and China. The rising number of initiatives undertaken by major vendors to assist patients in these countries is a significant contributor to the rise in sales of breast cancer mAbs in these countries. Moreover, the growing awareness about breast cancer and the available treatment alternatives will also propel growth prospects for the market growth in APAC.

Competitive landscape and key vendors

The competitive environment in this market is likely to intensify in the coming years with the increase in technological innovations, product extensions, and an increase in the number of mergers and acquisitions. Several major pharmaceutical companies that are adopting these strategies are anticipated to grow inorganically during the forecast period and increase their revenue. The probability of vendors entering this market is high owing to the high market potential, however, the presence of highly stringent guidelines to manufacture breast cancer mAbs will restrict them.

Leading vendors in the market are -

  • F. Hoffmann-La Roche
  • Amgen
  • Mylan

Other prominent vendors in the breast cancer mAbs market include Actavis, Array BioPharma, AstraZeneca, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industries, Synta Pharmaceuticals, and Teva Pharmaceuticals.

Segmentation by type of mAbs and analysis of the breast cancer mAbs market

  • Naked mAbs
  • Conjugated mAbs

During 2015, the naked mAbs dominated the breast cancer mAbs market and accounted for more than 91% of the total market share. Naked mAbs do not have a radioactive material or drug attached to them, and are the most commonly used mAbs. Though they work by attaching themselves to specific antigens, naked mAbs attach to diseased cells to act as a marker for the body’s own immune system to destroy them. Some of the approved naked mAbs by the US FDA include Herceptin (trastuzumab) and Avastin (bevacizumab).

Segmentation by end-users and analysis of the breast cancer mAbs market

  • Hospitals
  • Retail pharmacies

Retail pharmacies are the largest end-users of mAbs and occupied around 52% share of the overall market during 2015. Retail pharmacies also provide a large customer base for mAbs. Individuals with breast cancer require mAbs as a targeted therapy. This helps in the success of primary treatment and prevents relapse of the disease. These drugs can be easily obtained from retail pharmacies for use in hospital settings.

 Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global breast cancer mAbs market?
  • What are the key market trends impacting the growth of the global breast cancer mAbs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global breast cancer mAbs market?
  • What are the market opportunities and threats faced by the vendors in the global breast cancer mAbs market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of the global breast cancer mAbs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Breast cancer: Overview

  • Understanding the disease
  • Treatment regimen for breast cancer
  • Overview of mAbs

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by type of mAbs

  • Naked mAbs
  • Conjugated mAbs

PART 09: Market segmentation by end-user

  • Hospitals
  • Retail pharmacies

PART 10: Geographical segmentation

  • Global breast cancer mAbs market by geographical segmentation 2015-2020
  • Breast cancer mAbs market in Americas
  • Breast cancer mAbs market in EMEA
  • Breast cancer mAbs market in APAC

PART 11: Market drivers

  • Reimbursement benefits for breast cancer mAbs
  • Increase in demand for breast cancer ADCs
  • Huge market potential for breast cancer mAbs owing to product approvals
  • Exposure to risk factors

PART 12: Impact of drivers

PART 13: Market challenges

  • Absence of adequate diagnosis and screening procedures for early detection
  • High manufacturing costs coupled with stringent regulations
  • Threat from chemotherapy and off-label drugs
  • Difficulties in patient recruitment for conducting clinical trials

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Emergence of targeted and combination therapies for breast cancer
  • Growing focus of vendors on untapped markets
  • Emergence of biosimilars
  • Outsourcing of biosimilar manufacturing activities
  • Need for high investment in R&D

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Roche
  • Amgen
  • Mylan
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>